
Sign up to save your podcasts
Or
How do STAMP inhibitors differ from ATP-competitive tyrosine kinase inhibitors (TKIs) when treating chronic myeloid leukemia (CML)?
Credit available for this activity expires: 03/13/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/chronic-myeloid-leukemia-2025-update-novel-targets-and-2025a10005pm?ecd=bdc_podcast_libsyn_mscpedu
4.3
2323 ratings
How do STAMP inhibitors differ from ATP-competitive tyrosine kinase inhibitors (TKIs) when treating chronic myeloid leukemia (CML)?
Credit available for this activity expires: 03/13/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/chronic-myeloid-leukemia-2025-update-novel-targets-and-2025a10005pm?ecd=bdc_podcast_libsyn_mscpedu
13 Listeners
313 Listeners
107 Listeners
173 Listeners
864 Listeners
494 Listeners
688 Listeners
18 Listeners
278 Listeners
255 Listeners
3,324 Listeners
137 Listeners
1,113 Listeners
8,004 Listeners
193 Listeners
60 Listeners
8 Listeners
426 Listeners
315 Listeners